Avalanche {{AVAX}} and Aptos {{APT}}, all of which fell 8%-9% before paring some of the losses. The broad-market benchmark CoinDesk 20 Index (CD20) declined 6%.

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.